MétaCan
Menu
Back to cohort
Record W4408889678 · doi:10.1158/1078-0432.ccr-24-3475

Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential

2025· article· en· W4408889678 on OpenAlexaff
Walter M. Gregory, Thomas J. Prior, JB Bartlett, Pieter Sonneveld, Meletios Α. Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry Façon

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsHotel Dieu Hospital
FundersJanssen Research and DevelopmentNational Cancer Institute
KeywordsMinimal residual diseaseClinical trialMedicineOncologyResidualDiseaseMultiple myelomaSelection (genetic algorithm)Internal medicineComputer scienceMachine learningAlgorithmLeukemia

Abstract

fetched live from OpenAlex

PURPOSE: We designed mathematical models to describe and quantify the mechanisms and dynamics of minimal residual disease (MRD) in order to better understand these MRD dynamics; inform future treatment design, including when to stop or change treatment; and extrapolate from current progression-free survival (PFS) times to predict future PFS curves. EXPERIMENTAL DESIGN: This study aims to model individual sequential MRD data from phase III clinical trials (MAIA, CASTOR, and POLLUX) using previously developed mathematical models, which will be modified as needed to accurately reflect the actual MRD data. These models will then be used to project PFS curves into the future. RESULTS: Patients with low MRD values either showed rapid disease regrowth, or the MRD values remained low for a prolonged period. Treatment seemed to be most effective in terms of cell kill within the first 6 to 12 months. Regrowth rates were correlated with estimated initial residual disease, particularly in MRD-negative patients. Three-year model extrapolations of PFS were closely comparable with clinical trial data. CONCLUSIONS: This model could provide early prediction of PFS outcomes, which otherwise takes lengthy periods of time to observe in clinical trials. Patients showing rapid rebound from low MRD values may benefit from adding another treatment before reaching progressive disease. The MRD analyses and results presented, such as the results about efficacy occurring early in the first 6 to 12 months, may help guide the development and selection of optimal regimens. Longer follow-up periods and application to other trials and datasets are required to substantiate these findings.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.012
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.232
GPT teacher head0.533
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207